Risk factors of superinfection following imipenem/cilastatin therapy in hospitalised patients with acute exacerbations of severe chronic obstructive pulmonary disease

International Journal of Clinical Practice

Volumn 60, Issue 7, 2006, Pages 806-811

  Ding, Xuhong ^a   Wu, X ^a   Peng, Y ^a   Hu, S ^a   Nie, H ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Clinical trials; COPD; Imipenem; Intensive care unit; Superinfection

Indexed keywords

ANTIINFECTIVE AGENT; CILASTATIN; IMIPENEM; PROTEINASE INHIBITOR;

ACUTE DISEASE; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG COMBINATION; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MALE; MIDDLE AGED; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR; SUPERINFECTION;

ACUTE DISEASE; AGED; ANTI-BACTERIAL AGENTS; CILASTATIN; DRUG COMBINATIONS; FEMALE; HOSPITALIZATION; HUMANS; IMIPENEM; INTENSIVE CARE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RISK FACTORS; SUPERINFECTION;

EID: 85047688797     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00829.x     Document Type: Article

References (12)

1. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state of the art review. Clin Microbiol Rev 2001; 14: 336-63. (Pubitemid 32294674)
2. Pela R, Marchesani F, Agostinelli C et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53: 262-7. (Pubitemid 28461652)
3. Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-505.
4. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. Antimicrob Agents Chemother 1994; 38: 547-57. (Pubitemid 24072247)
5. Hamacher J, Vogel F, Lichey J et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalized patients - a comparison of meropenem and imipenem/cilastatin. COPD Study Group. J Antimicrob Chemother 1995; 36 (Suppl. A): 121-33.
6. Torres A, Bauer TT, León-Gil C et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000; 55: 1033-9.
7. Caldwell JW, Singh S, Johnson RH. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. J Antimicrob Chemother 1999; 43 (Suppl. A): 129-34. (Pubitemid 29123512)
8. Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD 2003 update. Eur Respir J 2003; 22: 1-2. (Pubitemid 36896461)
9. Anthonisen NR, Manfreda J, Warren CPW et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. (Pubitemid 17009877)
10. Soler N, Ewig S, Torres A et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-22.
11. Zalacain R, Sobradillo V, Amilibia J et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 343-8. (Pubitemid 29086831)
12. Monsó E, Rosell A, Bonet G et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999; 13: 338-42. (Pubitemid 29086830)